Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | CISD2 | Q8N5K1 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838909 | 0.79 | ADORA1 (0.61) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL20838929 | 0.79 | HPGD (0.60) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL20838914 | 0.77 | ADORA1 (0.58) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL20838898 | 0.75 | ADORA1 (0.58) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL20838899 | 0.74 | ADORA1 (0.62) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL20838922 | 0.73 | ADORA1 (0.58) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL15715922 | 0.70 | ADORA1 (1.00) | ALDH1A1ADORA1MAPTGAAKDM4E | |
| SCHEMBL20852895 | 0.69 | ADORA1 (0.55) | ALDH1A1SMN1; SMN2HPGDKMT2ALMNA | |
| SCHEMBL20838918 | 0.68 | ADORA1 (0.57) | ALDH1A1SMN1; SMN2HPGDKMT2AADORA1 | |
| SCHEMBL20838917 | 0.68 | CISD2 (0.84) | ALDH1A1ADORA1MAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 4054/4885SMN1; SMN2 4684/4885HPGD 3566/4885 |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | HAVCR2, ZC3HAV1, HCCS | ALDH1A1 4054/4885SMN1; SMN2 4684/4885HPGD 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.